ClinicalTrials.gg
RecruitingNCT04305834Updated Oct 16, 2026

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

A Phase 2 interventional study of Abemaciclib and Questionnaire Administration in Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma and Metastatic Breast Carcinoma, sponsored by City of Hope Medical Center. Recruiting at 6 sites in United States. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by City of Hope Medical Center · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Jun 2020; still recruiting 6 years 5 months later.
Updated Oct 16, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.

Planned enrollment
38th of 55
43 · median 120
Started
2020
with 9 others
Phase 2
27 of 55
12 open now
Primary completion
2027-05
later than 16 of 33 live
Registered
23rd of 55
by date
Lead sponsor
1 of 55
City of Hope Medical Center

Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 38th largest by planned enrollment, is one of 10 that started in 2020, is one of 27 in phase 2, reaches primary completion later than 16 of the 33 other live ones, and was the 23rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing abemaciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.

Read the detailed description

PRIMARY OBJECTIVE:

I. To estimate the incidence of grade 3 or higher toxicities attributed to abemaciclib monotherapy in adults aged 70 or older with hormone receptor positive metastatic breast cancer.

SECONDARY OBJECTIVES:

I. To describe the full toxicity profile including all grade 2 and higher adverse events, and patient-reported adverse events (AEs) using Patients Reported Outcomes (PRO)-Common Terminology Criteria for Adverse Events (CTCAE) measures.

II. To describe rates of dose reductions, dose holds, treatment discontinuations due to factors other than progression, and hospitalizations.

III. To estimate median (and 95% confidence interval [CI]) failure-free survival, progression-free survival and overall survival.

IV. To describe the results of Was It Worth It (WIWI) and Overall Treatment Utility (OTU) questionnaires.

V. To describe the rate of adherence to abemaciclib. VI. To determine average plasma steady-state abemaciclib Ctrough concentrations.

VII. To evaluate the association of adherence rate with abemaciclib plasma t-rough concentrations.

VIII. To describe associations between cancer-specific, comprehensive Geriatric Assessment (cGA) scores and the incidence of toxicities and their grade.

EXPLORATORY OBJECTIVE:

I. To determine the association between biomarkers of aging and grades 3 or higher toxicity.

OUTLINE:

Patients receive abemaciclib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days, then every 6 months for 2 years.

03

Conditions studied

  • Anatomic Stage IV Breast Cancer AJCC v8
  • Hormone Receptor Positive Breast Carcinoma
  • Metastatic Breast Carcinoma
  • Prognostic Stage IV Breast Cancer AJCC v8

Browse trials for

04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented of the participant
  • Age >= 70 years
  • > 6 months
  • Ability to read and understand English or Spanish
  • Measurable or non-
  • or cytologically confirmed diagnosis of:

    • Estrogen-receptor positive and/or progesterone receptor positive breast cancer determined by immunohistochemistry (IHC) methods according to the local institution standard protocol
    • -negative breast cancer defined as negative if the IHC status is 0 or 1+, or if IHC is 2+ and in situ hybridization assay is negative per American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines
  • Radiographically confirmed breast cancer
  • Progressed on prior endocrine therapy or palbociclib or ribociclib or chemotherapy
  • Patients who received chemotherapy recovered from the acute side effects to prior cancer therapy (except alopecia or residual grade 2 peripheral neuropathy) to =\< grade 1 or baseline. A of at least 21 days is required between last chemotherapy dose and randomization (provided the patient did not receive radiotherapy)
  • Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and randomization
  • Absence of central nervous system (CNS) involvement unless they meet ONE of the following criteria:

    • Untreated (e.g., lesions \< 1 cm) not needing immediate local therapy
    • Previously treated brain metastases not needing immediate local therapy

      • At least 4 weeks from the last date of prior therapy completion (including radiation and/or surgery) to starting the study treatment
      • Clinically stable CNS tumor at the time of screening and not receiving and/or enzyme-inducing anti-epileptic medications for brain metastases
  • Absence of interstitial lung disease/pneumonitis
  • (ANC) >= 1.5 X 10\^9/L
  • >= 100 x 10\^9/L
  • >= 8 g/dL

    • (Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion)
  • In the absence of liver metastases, (ALT) and aspartate aminotransferase (AST) =\< 3.0 x (ULN)

    • If the patient has liver metastases, ALT and AST \< 5 x ULN
  • In patients without Gilbert's syndrome, total =\< 1.5 x ULN; In patients with Gilbert's syndrome, total bilirubin =\< 2.0 x ULN or direct bilirubin within normal limits (WLN)
  • of >= 30 mL/min per 24 hour urine test or the Cockcroft-Gault formula

Exclusion criteria

Exclusion Criteria:

  • Major surgery within 14 days prior to receiving study drug or has not recovered from major side effect
  • Patient is currently receiving any of the prohibited medications detailed below and cannot be discontinued 7 days prior to starting study drug

    • Other therapy should be given to participants
    • Anticancer agents other than the study medications administered as part of this study protocol should be given to participants. If such agents are required for a participant then the participant must first be withdrawn from the study
    • Co-medication that may interfere with study results; e.g. immune-suppressive agents other than , such as systemic cyclosporine and tacrolimus are prohibited during the treatment phase of the study, unless discussed with principal investigator felt to be of low clinical risk to the participant
    • Use of herbal medications may have unknown interactions with the metabolism of the study agents, and therefore are prohibited from use during the treatment phase of the trial
  • Known to any of the of abemaciclib
  • Active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known positivity or with known active or C (for example, hepatitis B surface antigen positive). Screening is not required for enrollment
  • Impairment of gastrointestinal (GI) function or GI disease that in the investigator's opinion may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
  • History of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest
  • Patient has any other concurrent severe or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis)
  • Inability to swallow oral medications
  • Serious or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated \< 30 ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline grade 2 or higher diarrhea)
  • History of non-compliance to medical regimen
  • Patients with a prior diagnosed within 2 years and with evidence of disease (except adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (estimated)

Study arms

  • Experimental
    Treatment (abemaciclib)

    Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Drug: Abemaciclib · Other: Questionnaire Administration

Interventions

  • Given PO

    Also known as: LY-2835219, LY2835219, Verzenio

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Incidence of grade 3 or higher toxicities

    Adverse events will be characterized using the descriptions and grading scales found in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v). 5.0.

    Time frame: Up to 30 days post treatment

Secondary outcomes

  1. Incidence of toxicities

    Toxicities will be graded and named according to CTCAE v. 5.0.

    Time frame: Up to 30 days post treatment

  2. Incidence of toxicities

    Toxicities will be captured by Patient Reported Outcome (PRO)-CTCAE.

    Time frame: Up to cycle 6

  3. Dose reductions

    Will assess rates of dose reductions.

    Time frame: Up to cycle 6

  4. Dose holds

    Will assess rates of dose holds.

    Time frame: Up to 30 days post treatment

  5. Treatment discontinuations due to factors other than progression

    Will assess rates of treatment discontinuations.

    Time frame: Up to 30 days post treatment

  6. Hospitalizations

    Will assess rates of hospitalizations.

    Time frame: Up to 2 years post treatment

  7. Time to end of treatment

    Will estimate median (and 95% confidence interval \[CI\]) failure-free survival using Kaplan-Meier estimates and through Cox regression to adjust for covariates.

    Time frame: Up to end of treatment

  8. Progression free survival

    Will estimate median (and 95% CI) progression-free survival using Kaplan-Meier estimates and through Cox regression to adjust for covariates.

    Time frame: Up to 2 years post treatment

  9. Overall survival

    Will estimate median (and 95% CI) overall survival using Kaplan-Meier estimates and through Cox regression to adjust for covariates.

    Time frame: Up to 2 years post treatment

  10. Was It Worth It (WIWI) response

    Will be assessed using the WIWI questionnaire.

    Time frame: Up to end of treatment

  11. Overall treatment utility (OTU) response

    Will be assessed using the OTU questionnaire.

    Time frame: Up to end of treatment

  12. Adherence to abemaciclib

    Adherence defined as taking 90% of scheduled doses per cycle. Scheduled doses are assigned doses for the participant which may vary per participant depending on whether or not there a hold in treatment. Adherence will be calculated based on consolidation of pill diary with returned unused pills, and, for City of Hope (COH) Duarte patients, Medication Event Monitoring bottle caps.

    Time frame: Up to end of treatment

  13. Average plasma steady-state abemaciclib C-trough concentrations

    Time frame: Up to 2 years post treatment

  14. Pharmacokinetic (PK) parameter of plasma trough concentration

    Will evaluate the association of adherence rate with abemaciclib plasma trough concentrations.

    Time frame: Up to 2 years post treatment

  15. Geriatric assessment scores

    Domains include: functional status, co-morbid medical conditions, cognitive function, nutritional status, social support and psychological state, and a review of medications.

    Time frame: Up to 2 years post treatment

  16. Incidence of toxicities attributable to agent

    Graded by CTCAE v 5.0.

    Time frame: Up to 2 years post treatment

Other outcomes

  1. Biological age via deoxyribonucleic acid (DNA) methylation level

    Time frame: Up to 2 years post treatment

  2. Genome-wide methylome and transcriptome analyses

    Time frame: Up to 2 years post treatment

  3. Incidence of toxicities at least possibly attributable to agent

    Graded by CTCAE v 5.0.

    Time frame: Up to 2 years post treatment

07

Study locations

6 of 6 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for May 2027, 83 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 83 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

Start moved once since we started tracking on Sep 25, 2026: Mar 2020 → Jun 2020, on Oct 16, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → May 2027, on Oct 1, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → May 2027, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2020
First posted
Mar 12, 2020
StartActual
Jun 5, 2020was Mar 2020
Primary completionEst.
May 21, 2027was Aug 2026
CompletionEst.
May 21, 2027was Aug 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 25, 2020→Jun 5, 2020
Oct 16, 2026
Primary completion
Aug 21, 2026→May 21, 2027
Oct 1, 2026
Study completion
Aug 21, 2026→May 21, 2027
Oct 1, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Roswell Park Comprehensive Cancer Center · Buffalo, United StatesContact •••9355→•••9355
across 2 updates, Oct 1, 2026 – Oct 16, 2026
Show all 2 updates
  1. Oct 16, 2026
    Start date Mar 25, 2020→Jun 5, 2020
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Roswell Park Comprehensive Cancer Center · Buffalo, United StatesContact •••9355→•••9355
    + 1 other change: verification date
  2. Oct 1, 2026
    Primary completion Aug 21, 2026→May 21, 2027
    Study completion Aug 21, 2026→May 21, 2027
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Roswell Park Comprehensive Cancer Center · Buffalo, United StatesContact •••9355→•••9355
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04305834
Responsible party
Sponsor
First posted
Mar 12, 2020
Start date
Jun 5, 2020
Primary completion
May 21, 2027 (estimated)
Completion
May 21, 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Joanne Mortimer, MD
Contact
jmortimer@coh.org
626-359-8111
Joanne Mortimer, MD
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion